Ultragenyx Pharmaceutical Quote - 0LIF

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

64.79

Bid

0.00

Offer

0.00

Volume

283

0.00 Day's Range 0.00

64.79 52 Week Range 64.79

Market Cap

5.32B

Previous Close

64.79

Open

Last Trade

43.55

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

435

Shares Outstanding

82,114,000

Dividend Yield

PE Ratio

-5.75

Earnings Per Share (EPS)

-7.39

Revenue

434.25M

Net Profit

-606.64M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ultragenyx.com

Headquarters

Wilmington, Delaware, USA

Founded

Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0LIF. The last closing price for Ultragenyx Pharmaceutical was US$64.79. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 64.79 to US$ 64.79.

Ultragenyx Pharmaceutical currently has 82,114,000 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$5.32 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -5.75.

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial...

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial...

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia...

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza®...

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	64.79	64.79	64.79	387	64.79	DE
4	64.79	64.79	64.79	528	64.79	DE
12	64.79	64.79	64.79	435	64.79	DE
26	64.79	64.79	64.79	463	64.79	DE
52	64.79	64.79	64.79	357	64.79	DE
156	64.79	64.79	64.79	524	64.79	DE
260	64.79	64.79	64.79	329	64.79	DE

0LIF - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?

The current share price of Ultragenyx Pharmaceutical is US$ 64.79

How many Ultragenyx Pharmaceutical shares are in issue?

Ultragenyx Pharmaceutical has 82,114,000 shares in issue

What is the market cap of Ultragenyx Pharmaceutical?

The market capitalisation of Ultragenyx Pharmaceutical is USD 5.32B

What is the 1 year trading range for Ultragenyx Pharmaceutical share price?

Ultragenyx Pharmaceutical has traded in the range of US$ 64.79 to US$ 64.79 during the past year

What is the PE ratio of Ultragenyx Pharmaceutical?

The price to earnings ratio of Ultragenyx Pharmaceutical is -5.75

What is the cash to sales ratio of Ultragenyx Pharmaceutical?

The cash to sales ratio of Ultragenyx Pharmaceutical is 8.04

What is the reporting currency for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical reports financial results in USD

What is the latest annual turnover for Ultragenyx Pharmaceutical?

The latest annual turnover of Ultragenyx Pharmaceutical is USD 434.25M

What is the latest annual profit for Ultragenyx Pharmaceutical?

The latest annual profit of Ultragenyx Pharmaceutical is USD -606.64M

What is the registered address of Ultragenyx Pharmaceutical?

The registered address for Ultragenyx Pharmaceutical is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Ultragenyx Pharmaceutical website address?

The website address for Ultragenyx Pharmaceutical is www.ultragenyx.com

Which industry sector does Ultragenyx Pharmaceutical operate in?

Ultragenyx Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SYMESupply@me Capital Plc	0.0065p (120.34%)	10.84B
SCGLSealand Capital Galaxy Limited	2.50p (58.23%)	23.72M
LSTLight Science Technologies Holdings Plc	3.30p (29.41%)	5.55M
CADCadogan Energy Solutions Plc	6.00p (26.32%)	973.88k
ANICAgronomics Limited	5.10p (18.88%)	23.49M
METMetir Plc	0.825p (-96.07%)	406.55k
WG.Wood Group (john) Plc	30.18p (-53.82%)	83.27M
NEXNNexxen International Ltd	405.00p (-47.74%)	450.71k
ONCOncimmune Holdings Plc	4.10p (-40.79%)	3.78M
TLYTotally Plc	4.85p (-27.07%)	6.21M
SYMESupply@me Capital Plc	0.0065p (120.34%)	10.84B
CORCorpus Resources Plc	0.018p (-2.70%)	1.03B
ROCKRockfire Resources Plc	0.1175p (-14.55%)	731.57M
NTVONativo Resources Plc	0.0015p (0.00%)	370.56M
MSMNMosman Oil And Gas Limited	0.039p (-4.88%)	235.98M

KIPK 11 minutes ago

JONDOEUK,
This thing is more air than oxygen .. Just like your NVCR...

You know who is coming?? 👀

NVCR

mrfence 12 minutes ago

You've put yourself on ignore, lol!

FNMA

KIPK 14 minutes ago

Try harder jondoeuk. If as you colluded......

>>>>>>>Finally, NWBO is a shitco scam >>>>

Why are you so afraid of NWBO....

I AM SURE YOU KNOW WHY!!

NWBO

SilkRoad 17 minutes ago

Drop in and go using existing infrastructure. That was the drumbeat we heard many moons ago. But every step of the way they have to seemingly build a new facility, bring in and/or modify equipment, add a lab, add testing, get a license, open an office, and bring in outside experts. I think you ar

KBLB

Peter J 19 minutes ago

no matter what desperate attempts they try in order to attract buyers there is something called common sense that most investors use to stay away from a disaster like ERHC.
Come on badog, get real please: talking solely about your and ssc's motives for posting here can hardly qualify as tryin

ERHE

chereb19 26 minutes ago

https://investorshub.advfn.com/uimage/uploads/2025/2/16/kprkvScreenshot_2025-02-16-11-06-05-307_com.twitter.android-edit.jpg

RDGL

Peter J 29 minutes ago

Badog, read the 6th post, how relevant, again!

https://www.lse.co.uk/profiles/supercooper/
I also don't post on boards where I have no holdings. Why on earth are you posting on the Tlw board if you have no interest Long or Short. Trying to make yourself feel good by denigrating

ERHE

sharkey1 30 minutes ago

Hypothetical press release:

Tuesday AM.
Elite is in talks with XYZ company, no name yet, and they are huge with billions
in the market cap, and there stock is worth 30 bucks a share.
And theres a leak as to who it is.
Elites stock will shoot up fast to me

XYZ

baltimorebullet 34 minutes ago

One wildcard no one is mentioning is other indebted developed countries may follow the U.S. and begin to reduce their government employee headcounts.
That could slow down the EMA among many other things.

AVXL

sharkey1 35 minutes ago

Can’t sleep, waiting for the M and A news that could come Tuesday morning.
It’s a 3 day weekend, they could be working on anything. Instead of merger Monday
could be merger Tuesday.

ELTP

chereb19 39 minutes ago

Glad you're on board @I-Blow

Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, is pleased to report several significant outcomes after its signature product, IsoPet®, was used to

RDGL

EZ2 39 minutes ago

17-12-22-23 ..... Gl !!

EZ2 45 minutes ago

Hi Red !

cojoboy 47 minutes ago

Hey...you said it..not me.????...but..I would invest in a Death Star..🤔🤔🤔🤔

PHIL

Dumb&dumber4long 51 minutes ago

Taking a small position is more likely, when technicals are not fully aligned (to one’s standards, which I did for FOMO.
However, a more substantial position warrants patience.
If it results in averaging up a little, then be it.
If it has not bottomed yet, then it’ll be averagin

TNXP

10thMountain 54 minutes ago

FDCT Tweet with chart..Only 33 million float. It’s bouncing off the 50 day ma. MACD is curly up. The last time I pounded the table, it went from low pennies to .16! The next big move is in the making….

https://x.com/randylus/status/1890790544235704558?s=46

FDCT

lovethatgreen 1 hour ago

According to the last q in September last shares issued in 2023 was in dec and then there were no new shares issued until June of 2024. All of those shares would have been included in the OS . So if old 2022 debt is being sold why is the OS getting larger unless they they are issuing new shares fo

AFFU

SkeBallLarry 1 hour ago

Trump on DOGE: “We literally started off with >

14 or 15 young geniuses.
Now we have 100 young geniuses.
And what’s happened…
People are calling up from all over the country wanting to help Elon Musk.”
https://x.com/unusual_whales/status/18907783424016672

SkeBallLarry 1 hour ago

DOGE scores big court win, allowed access data on 3 federal agencies

Musk hailed the decision by reposting its news on X with the caption: 'LFG'

https://www.foxnews.com/politics/doge-scores-big-court-win-allowed-access-data-3-federal-agencies

SkeBallLarry 1 hour ago

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Ultragenyx Pharmaceutical Inc (0LIF)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Ultragenyx Pharmaceutical Inc

Ask ADVFN Intelligence (AI)

0LIF Latest News

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

0LIF - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Ultragenyx Pharmaceutical Inc (0LIF) Share Price

Ultragenyx Pharmaceutical Inc (0LIF)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Ultragenyx Pharmaceutical Inc

Ask ADVFN Intelligence (AI)

0LIF Latest News

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

0LIF - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free